Chief Executive Fredric Price says that if he can find a partner for a second experimental drug, for use in open-heart surgery, the company could be close to break-even for the fourth quarter of 2004.

FORBES: BioMarin Gets Ready To Bloom

Sanofi could save money by chopping heads and still make use of experimental drugs for melanoma, kidney transplants and leg clots that Bristol is developing.

FORBES: Why Bristol And Sanofi Shouldn't Merge

The firm plans to use some of the smallpox proceeds to help develop its experimental vaccines for West Nile virus and dengue fever.

FORBES: Biotechs See Dollar Signs In War